In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …
Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects
S Lusvarghi, W Wang, R Herrup… - Journal of …, 2022 - Am Soc Microbiol
Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical …
CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical …
Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2
Neutralizing antibodies (nAbs) to SARS-CoV-2 hold powerful potentials for clinical
interventions against COVID-19 disease. However, their common genetic and biologic …
interventions against COVID-19 disease. However, their common genetic and biologic …
Prepare for the future: dissecting the spike to seek broadly neutralizing antibodies and universal vaccine for pandemic coronaviruses
L Vangelista, M Secchi - Frontiers in Molecular Biosciences, 2020 - frontiersin.org
Learning from the lengthy fight against HIV-1, influenza, and Ebola virus infection, broadly
neutralizing antibodies (bnAbs), directed at conserved regions of surface proteins crucial to …
neutralizing antibodies (bnAbs), directed at conserved regions of surface proteins crucial to …
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
Numerous antibodies that neutralize SARS-CoV-2 have been identified, and these generally
target either the receptor-binding domain (RBD) or the N-terminal domain (NTD) of the viral …
target either the receptor-binding domain (RBD) or the N-terminal domain (NTD) of the viral …
[HTML][HTML] Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization
In vitro antibody selection against pathogens from naïve combinatorial libraries can yield
various classes of antigen-specific binders that are distinct from those evolved from natural …
various classes of antigen-specific binders that are distinct from those evolved from natural …
Structure-guided antibody cocktail for prevention and treatment of COVID-19
Development of effective therapeutics for mitigating the COVID-19 pandemic is a pressing
global need. Neutralizing antibodies are known to be effective antivirals, as they can be …
global need. Neutralizing antibodies are known to be effective antivirals, as they can be …
[HTML][HTML] Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies
Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals
previously infected with SARS-CoV-2, but the relative contributions of these different …
previously infected with SARS-CoV-2, but the relative contributions of these different …
Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is continuously
evolving, and this poses a major threat to antibody therapies and currently authorized …
evolving, and this poses a major threat to antibody therapies and currently authorized …
Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Z Liu, LA VanBlargan, LM Bloyet, PW Rothlauf… - BioRxiv, 2020 - biorxiv.org
Although neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of
most COVID-19 vaccines and being developed as therapeutics, escape mutations could …
most COVID-19 vaccines and being developed as therapeutics, escape mutations could …